Galmed Pharmaceuticals (GLMD)
(Real Time Quote from BATS)
$9.58 USD
+0.23 (2.46%)
Updated Sep 23, 2024 12:54 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 61 - 80 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Final Program for Our Third Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Program for Our Third Annual NASH Investor Conference, October 21, New York
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - The Liver Meeting Abstracts Part 2: Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
With the Start of ARMOR, Aramchol Is Officially a Phase 3 NASH Asset; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
2Q19 Recap: Just Weeks Away From the Initiation of Phase 3 ARMOR Study in NASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Join Our Three-Part NASH Doc Series on "How Large is the NASH Opportunity?"
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare -Recap of Our 27 Most Valuable Industry Notes in 2019
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare -Recap of 34 Notes From Our Coverage of EASL 2019 and AASLD
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
1Q19 - Don''t Underestimate ARMOR Phase 3 Trial - Timing
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
ARMOR Set to Make Aramchol the Next Phase 3 NASH Contender; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Following EOP2 Meeting, ARMOR Design Protocol Is Set for a 3Q19 Pivotal Trial Start; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - Walk Through Yas'' Shoes at EASL - Our EASL Roadmap
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - Part 2: Digging Through ICPT EASL Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
NASH Weekly: Should You Go to EASL With Late Breakers Abstracts Revealed?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y